NRx in Radnor Cleared to Use Its COVID-19 Drug in Country of Georgia

By

NRx has a new drug therapy to treat critically-ill COVID-19 patients.
Image via Marco Verch.

With COVID-19 cases growing by 1,000 cases a day, the country of Georgia has issued an emergency authorization to use a COVID-19 therapy, Zyesami, developed by NRx, a Radnor pharmaceutical company, writes John George for Philadelphia Business Journal.

The emergency authorization came from Georgia’s prime minister and minister of health.

With the rise in cases, Georgia is seeing more hospitalizations, triggered by the Delta variant.

NRx CEO Dr. Jonathan Javitt said NRx is sending investigators to Georgia to teach physicians there how to administer the drug.

“The repeating ferociousness of this pandemic is of great concern, and we hope Zyesami can have a real-world impact, comparable to what we saw in our clinical trials,” Javitt said.

NRx filed with the FDA in June for an emergency use authorization to use Zyesami to treat respiratory failure in critically-ill COVID-19 patients.

The company’s stock soared last week after NRx announced it had received a validation of its first commercial COVID-19 therapy use of Zyesami.

The therapy provides at least one year of stability.

The stock doubled in value from $12.38 per share to $24.77 per share before retreating earlier this week. It was down almost 8 percent Wednesday afternoon at $16.50 a share. 

Read more at Philadelphia Business Journal about NRx.

Join Our Community

Never miss a Delaware County story!

"*" indicates required fields

Hidden
DT Yes
This field is for validation purposes and should be left unchanged.
Advertisement